These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 37357422)
1. Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3-d]pyrimidine derivatives as EGFR inhibitors. Sayed MTM; Halim PA; El-Ansary AK; Hassan RA Drug Dev Res; 2023 Sep; 84(6):1299-1319. PubMed ID: 37357422 [TBL] [Abstract][Full Text] [Related]
2. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells. Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
4. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking. Hassan RA; Hamed MIA; Abdou AM; El-Dash Y Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway. Seif SE; Mahmoud Z; Wardakhan WW; Abdou AM; Hassan RA Drug Dev Res; 2023 Aug; 84(5):839-860. PubMed ID: 37016480 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vitro antitumor evaluation of new thieno[2,3-d]pyrimidine derivatives as EGFR and DHFR inhibitors. Fouad MM; Ghabbour HA; Shehata IA; El-Ashmawy MB Bioorg Chem; 2024 Jul; 148():107401. PubMed ID: 38749115 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400 [TBL] [Abstract][Full Text] [Related]
9. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
10. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study. AboulWafa OM; Daabees HMG; Badawi WA Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112 [TBL] [Abstract][Full Text] [Related]
11. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Maher M; Kassab AE; Zaher AF; Mahmoud Z Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080 [TBL] [Abstract][Full Text] [Related]
12. Computer aided drug discovery (CADD) of a thieno[2,3- Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH J Biomol Struct Dyn; 2024 Mar; 42(5):2369-2391. PubMed ID: 37129193 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity. Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427 [TBL] [Abstract][Full Text] [Related]
14. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights. Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598 [TBL] [Abstract][Full Text] [Related]
15. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range. Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388 [TBL] [Abstract][Full Text] [Related]
16. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR Raghunath Khedkar N; Sindkhedkar M; Joseph A Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682 [TBL] [Abstract][Full Text] [Related]
17. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
19. Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFR Reda N; Mohamed KO; Abdou K; Helwa AA; Elshewy A Bioorg Chem; 2024 Apr; 145():107185. PubMed ID: 38350273 [TBL] [Abstract][Full Text] [Related]
20. Discovery of new thieno[2,3- Sobh EA; Dahab MA; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH Future Med Chem; 2023 Jul; 15(13):1167-1184. PubMed ID: 37529910 [No Abstract] [Full Text] [Related] [Next] [New Search]